- Advanced analytical methods integrating clinical trial and real-world data address key evidence gaps in rare, difficult-to-treat blood cancers
- Read more »
New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome
- Clinically meaningful improvements in skin symptoms reported as early as week 4 and sustained over the 48-week study period
- Data presented at [...] Read more »
Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease
SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) -- Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced the initiation of a [...] Read more »
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
- REC–4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)
- After 12 weeks [...] Read more »
Miltenyi Biomedicine stellt die Primäranalyse der zulassungsrelevanten DALY-2-EU-Studie zur Zweitlinientherapie des rezidivierten/refraktären großzelligen B-Zell-Lymphoms auf der 67. Jahrestagung der American Society of Hematology (ASH) vor
- Die Ergebnisse der DALY 2–EU–Studie zeigen, dass Zamtocabtagen Autoleucel (Zamto–cel) bei Patienten mit rezidiviertem/refraktärem [...] Read more »
À l’occasion de la 67e réunion annuelle de l’American Society of Hematology (ASH), Miltenyi Biomedicine présente l’analyse primaire de l’essai pivot DALY 2-EU pour le traitement de seconde ligne du lymphome à grandes cellules B en rechute ou réfractaire
- Les résultats de l’essai DALY 2–EU révèlent que le zamtocabtagene autoleucel (zamto–cel) présente une [...] Read more »
Miltenyi Biomedicine divulga análise primária do estudo principal do DALY 2-EU para linfoma de células B grandes recidivante/refratário de segunda linha na 67ª Reunião Anual da Sociedade Americana de Hematologia (ASH)
- Os resultados do DALY 2–UE mostram que o autoleucel de zamtocabtageno (zamto–cel) demonstrou superioridade clinicamente significativa em [...] Read more »
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
- DALY 2–EU results show zamtocabtagene autoleucel (zamto–cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B–cell lymphoma [...] Read more »
Sabin Vaccine Institute’s Investigational Marburg Vaccine Delivered to Ethiopia for Outbreak Response
WASHINGTON, Dec. 04, 2025 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute (Sabin) has sent more than 640 doses of its investigational cAd3–Marburg Vaccine to Ethiopia to support the [...] Read more »
NeOnc Technologies Reports Updated Clinical Results
CALABASAS, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi–Phase 2 clinical–stage biopharmaceutical company [...] Read more »